Bibliography
- FAULKNER MA, HILLEMAN DE: The economic impact of chronic obstructive pulmonary disease. Expert Opin Pharmacother. (2002) 3(3):219.
- NORMAN P: Therapeutic approaches to respiratory diseases excluding asthma: Trends from the patent literature 1997-2000. Expert Opin. Ther. Patents (2001) 11(2):307.
- MASSARO GD, MASSARO D: Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats. Nat. Med (1997) 3(6):675–677.
- ••The key demonstration of the possibility ofrepairing damaged lung with retinoids.
- BARNES PJ: New treatments for chronic obstructive pulmonary disease. Curr. Opin. Pharmacol (2001) 1(3):217–222.
- MASSARO D, MASSARO GD: Pulmonary alveolus formation: critical period, retinoid regulation and plasticity. Novartis Found Symp. (2001) 234:229–241.
- MCGOWAN S, JACKSON SK et al: Mice bearing deletions of retinoic acid receptors demonstrate reduced lung elastin and alveolar numbers. Am. j Respir Cell Mal Biol. (2000) 23(2):162–167.
- •Study in transgenic animals highlighting the significance of RAR-y receptors.
- MAO JT, GOLDIN JG, DERMAND J etal.: A pilot study of all- trans-retinoic acid for the treatment of human emphysema. Am. j Respir. Cut. Care Med. (2002) 165(5):718–723.
- •Partial clinical validation of this approach.
- ROCHE HOLDING AG: Annual Report2001.
- MAO CI BAILEY-HEALY I, GATER PR,BELLONI P: Effects Of R0444753: a synthetic retinoid agonist, on morphologic and lung function changes in a rat model of emphysema. Am. J. Respir. Crit. Care Med. (2002) 165:A916.
Websites
- Global Initiative for Chronic Obstructive Lung Disease: www.goldcopd.com/
- The FORTE Study: www.lung.med.ucla.edu/ Clinical%20Research/FORTE/
- Roche Holding AG, Half-Year Presentation to Investors, 15 August 2001: www.roche.com/home/media/med-corp/ med-corp- 200 1 /med-corp-detail-2001.htm?id 684 &media-language e